Is Ozempic the same as Semaglutide?

Ozempic is a Novo Nordisk brand name for a prescription product whose active ingredient is Semaglutide, a GLP-1 receptor agonist. Wegovy is another brand of the same molecule. Vancouver Island Peptides supplies Semaglutide as a research compound — not the branded pharmaceutical — synthesized domestically in Vancouver, BC.

How does Retatrutide compare to Ozempic?

Ozempic's active ingredient, Semaglutide, targets one receptor: GLP-1. Retatrutide targets three — GLP-1, GIP, and glucagon. The added glucagon activation increases energy expenditure alongside the appetite regulation both share, making Retatrutide the more comprehensive metabolic research compound of the two.

Can I buy Semaglutide and Retatrutide in Canada?

Both are available from Vancouver Island Peptides as research compounds synthesized domestically in Vancouver, BC. They are sold for laboratory and personal wellness research only, ship Canada-wide in discreet packaging, and are not approved by Health Canada for human use.

Which is stronger, Retatrutide or Semaglutide?

In early clinical research, the triple mechanism of Retatrutide has shown more pronounced metabolic effects than single-agonist Semaglutide. However, Semaglutide is far more extensively studied with a longer track record. The right choice depends on the specific research question.

← Vancouver Island Peptides / Blog

GLP-1 Research Peptides — Comparison

Retatrutide vs Ozempic (Semaglutide): The Next-Generation Comparison

July 8, 2026

If you have researched GLP-1 compounds in Canada, two names come up constantly: Ozempic — the brand everyone knows — and Retatrutide, the newer compound researchers are increasingly asking about. This guide explains exactly how they relate, where they differ mechanically, and what each means for metabolic research.

First, a Clarification: Ozempic Is a Brand, Semaglutide Is the Molecule

Ozempic and Wegovy are Novo Nordisk brand names for prescription products. Their active ingredient is Semaglutide, a GLP-1 receptor agonist. When researchers compare "Retatrutide vs Ozempic," the real comparison is Retatrutide vs Semaglutide — the underlying molecules. Vancouver Island Peptides supplies Semaglutide as a research compound, synthesized domestically in BC — not the branded pharmaceutical.

The Core Difference: One Receptor vs Three

This is the entire story in one line. Semaglutide activates a single receptor. Retatrutide activates three.

Compound	Receptor Targets	Generation
Semaglutide (Ozempic / Wegovy)	GLP-1	First — single agonist
Tirzepatide (Mounjaro)	GLP-1 + GIP	Second — dual agonist
Retatrutide	GLP-1 + GIP + Glucagon	Third — triple agonist

Semaglutide works purely through the GLP-1 pathway — regulating appetite, slowing gastric emptying, and supporting insulin response. Retatrutide keeps all of that and adds two more mechanisms:

GIP activation — enhances insulin sensitivity and energy balance
Glucagon receptor activation — increases energy expenditure and promotes fat mobilization, a mechanism Semaglutide does not have at all

What This Means in Research Terms

Semaglutide's single-pathway approach is the most extensively studied and validated of any GLP-1 compound — it has years of clinical data behind it and is the reference point the entire class is measured against. Retatrutide's triple mechanism is newer, with early-phase trials showing more pronounced metabolic effects, but a shorter research history.

Neither is universally "better." Semaglutide offers depth of evidence and a well-characterized profile; Retatrutide offers the broadest mechanistic coverage currently available. The right compound depends on the research question.

Sourcing Both in Canada

Both are available from Vancouver Island Peptides as domestic research compounds — synthesized at our Vancouver, BC lab partner, HPLC-verified to >99% purity, and shipped Canada-wide in discreet packaging. Unlike imported peptides, ours never cross a border, so there is no seizure risk and no cold-chain uncertainty.

View Semaglutide Canada View Retatrutide Canada

See also our companion guide: Tirzepatide vs Mounjaro — the dual agonist that sits between these two.

All products are intended for research and personal wellness purposes only. Not for human consumption. Not approved by Health Canada. Ozempic, Wegovy, and Mounjaro are registered trademarks of their respective owners (Novo Nordisk and Eli Lilly); Vancouver Island Peptides is not affiliated with, endorsed by, or sponsored by these companies, and does not sell their branded products. We supply generic research compounds only. Consult a qualified healthcare provider before use. Ships within Canada only.